CHF Solutions
Market Cap
US$5.5m
Last Updated
2020/02/17 00:45 UTC
Data Sources
Company Financials +
Executive Summary
CHF Solutions, Inc., a medical device company, focuses on the provision of solutions for patients suffering from fluid overload.
Rewards
Risk Analysis
Shareholders have been substantially diluted in the past year
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
Snowflake Analysis
Adequate balance sheet with limited growth.
Similar Companies
Share Price & News
How has CHF Solutions's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CHFS's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-20.6%
CHFS
2.4%
US Medical Equipment
1.8%
US Market
1 Year Return
-96.4%
CHFS
22.1%
US Medical Equipment
20.1%
US Market
Return vs Industry: CHFS underperformed the US Medical Equipment industry which returned 22.1% over the past year.
Return vs Market: CHFS underperformed the US Market which returned 20.1% over the past year.
Shareholder returns
| CHFS | Industry | Market | |
|---|---|---|---|
| 7 Day | -20.6% | 2.4% | 1.8% |
| 30 Day | -67.4% | 1.2% | 1.4% |
| 90 Day | -45.7% | 8.6% | 8.8% |
| 1 Year | -96.4%-96.4% | 23.0%22.1% | 22.7%20.1% |
| 3 Year | -100.0%-100.0% | 84.6%79.4% | 50.1%40.4% |
| 5 Year | -100.0%-100.0% | 117.3%94.6% | 72.9%53.9% |
Price Volatility Vs. Market
How volatile is CHF Solutions's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 months ago | Simply Wall St
Here's Why We're A Bit Worried About CHF Solutions's (NASDAQ:CHFS) Cash Burn Situation6 months ago | Simply Wall St
What Kind Of Investor Owns Most Of CHF Solutions, Inc. (NASDAQ:CHFS)?10 months ago | Simply Wall St
Is CHF Solutions, Inc. (NASDAQ:CHFS) Spending Too Much Money?Valuation
Is CHF Solutions undervalued compared to its fair value and its price relative to the market?
0.24x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CHFS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CHFS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CHFS is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: CHFS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CHFS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CHFS is good value based on its PB Ratio (0.2x) compared to the US Medical Equipment industry average (4x).
Next Steps
Future Growth
How is CHF Solutions forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
32.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CHFS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CHFS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CHFS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CHFS's revenue (48.4% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: CHFS's revenue (48.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CHFS's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has CHF Solutions performed over the past 5 years?
3.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CHFS is currently unprofitable.
Growing Profit Margin: CHFS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CHFS is unprofitable, but has reduced losses over the past 5 years at a rate of 3.4% per year.
Accelerating Growth: Unable to compare CHFS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CHFS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (7.1%).
Return on Equity
High ROE: CHFS has a negative Return on Equity (-413.14%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is CHF Solutions's financial position?
Financial Position Analysis
Short Term Liabilities: CHFS's short term assets ($6.1M) exceed its short term liabilities ($2.9M).
Long Term Liabilities: CHFS's short term assets ($6.1M) exceed its long term liabilities ($309.0K).
Debt to Equity History and Analysis
Debt Level: CHFS is debt free.
Reducing Debt: CHFS had no debt 5 years ago.
Balance Sheet
Inventory Level: CHFS has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if CHFS's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CHFS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CHFS has less than a year of cash runway if free cash flow continues to grow at historical rates of 8.1% each year.
Next Steps
Dividend
What is CHF Solutions's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate CHFS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CHFS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CHFS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CHFS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CHFS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.5yrs
Average management tenure
CEO
John Erb (70yo)
4.3yrs
Tenure
US$579,758
Compensation
Mr. John L. Erb has been the Chief Executive Officer and President of CHF Solutions, Inc. (also known as Sunshine Heart Inc.) since November 2015. Mr. Erb served as Director of Electromed, Inc. since Augus ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD579.76K) is about average for companies of similar size in the US market ($USD521.92K).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 4.3yrs | US$579.76k | 0.076% $4.2k | |
| Chief Financial Officer | 5.1yrs | US$392.42k | 0.000010% $0.5 | |
| Chief Commercial Officer | 0.8yrs | US$639.84k | no data | |
| Sr. Vice President of Operations & Engineering | 2.1yrs | no data | no data | |
| Sr. Vice President of Corporate Development & Technology | 0.9yrs | no data | no data | |
| VP, General Counsel | 1.5yrs | no data | no data | |
| Senior Vice President of Human Resources | 5.1yrs | no data | no data | |
| Senior Vice President of Commercial Operations | 1.3yrs | no data | no data | |
| Vice President of International Business Development | 1.5yrs | no data | no data |
1.5yrs
Average Tenure
51.5yo
Average Age
Experienced Management: CHFS's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 4.3yrs | US$579.76k | 0.076% $4.2k | |
| Independent Director | 8.5yrs | US$64.26k | 0.000010% $0.5 | |
| Lead Independent Director | 0yrs | US$71.76k | 0.000020% $1.1 | |
| Independent Non Executive Director | 6.9yrs | US$59.01k | 0.000020% $1.1 | |
| Independent Non-Executive Director | 3yrs | US$133.60k | 0.000030% $1.6 | |
| Independent Director | 0.4yrs | US$18.38k | no data |
6.9yrs
Average Tenure
65.5yo
Average Age
Experienced Board: CHFS's board of directors are considered experienced (6.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 411.8%.
Top Shareholders
Company Information
CHF Solutions, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: CHF Solutions, Inc.
- Ticker: CHFS
- Exchange: NasdaqCM
- Founded: 1999
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$5.471m
- Shares outstanding: 15.25m
- Website: https://www.chf-solutions.com
Number of Employees
Location
- CHF Solutions, Inc.
- 12988 Valley View Road
- Eden Prairie
- Minnesota
- 55344
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CHFS | NasdaqCM (Nasdaq Capital Market) | Yes | Ordinary Shares | US | USD | Feb 2012 |
| 22S3 | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Feb 2012 |
Biography
CHF Solutions, Inc., a medical device company, focuses on the provision of solutions for patients suffering from fluid overload. The company’s commercial product is the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. Its Aquadex FlexFlow system includes a console, and disposable blood set and catheter. The company sells its products to hospitals and clinics through its direct Salesforce in the United States; and through independent specialty distributors primarily in Brazil, Germany, Hong Kong, India, Italy, Singapore, Spain, Thailand, and the United Kingdom. The company was formerly known as Sunshine Heart, Inc. and changed its name to CHF Solutions, Inc. in May 2017. CHF Solutions, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/17 00:45 |
| End of Day Share Price | 2020/02/14 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.